Replies to post #796039 on NorthWest Biotherapeutics Inc (NWBO)

[Reefrad]

Why are you always so unclear? If you have something useful to say, say it. Otherwise why are you wasting your and our time?

[maverick_1]

BIG CLUE on the HUB of NAKED SHORTING POSTED too many many years ago

Your DISMISSIVENESS INFLEXIBLE MINDSETS & NEGLIGENCE
has been amply underscored since 2015 of the PATHOS

Perhaps a morsel of Redemption if you can UNLOCK this

WHALE of a ClueS
Barclays dark pool market manipulation”

“Naked shorting Barclays SEC”

“Dark pools and naked short selling research”

“Regulation of dark pools Barclays”

WHO has this in LinkedIn:

Barclays Investment Bank
9 years 8 months
Head of Equities, Americas
Barclays Investment Bank
December 2013 – April 2018 4 years 5 months
Greater New York City Area
Manage sales and trading organization, set overall strategy and point person for all regulatory / legal matters. Responsible for overall portfolio risk across all equities products in the region to include derivatives, convertibles, cash and ECM residual positions. Senior client relationships to include Hedge Fund Founders, CIOs, Head Traders, Long Only Managers and Asset Allocators. Identify and cultivate talent, set standards of excellence, lead and mentor in an ever-changing world. Flow derivative expert and student of the financial markets. Member BI Diversity Council and Member BCI Board.

Co-Head Equities Distribution, Americas
Barclays Capital
March 2012 – December 2013 1 year 10 months
Set client strategy across all equites products.
Manage personnel, distribution structure, and client outcomes.
Senior client relationships to include Hedge Fund Founders, CIOs, Head Traders, Long Only Managers and Asset Allocators”

IF you SOLVE & not providing any more clues

You are on the RIGHT PATH vs still lost in The JUNGLE whether NYC Tokyo or Hong Kong

DIFFERENT STROKES for DIFFERENT FOLKS

[attilathehunt]

Are you suggesting Merck is behind the manipulation until keytruda gets close to being off patent?

[Chiugray]

Maverick, Thanks for highlighting Andrew's post.
Excerpt:

14 | Final Perspective

Dark pools and derivatives can delay recognition of value, but they cannot defy the laws of settlement. Every borrowed share must be returned; every synthetic claim must locate a real certificate. In companies with concrete assets and imminent catalysts, those obligations converge on a date certain.

For Northwest Biotherapeutics, that date will come when regulators confirm what the underlying infrastructure already demonstrates: that its therapy can be manufactured and sold. When that confirmation arrives, the market will have to reconcile years of synthetic liquidity with the reality of limited float. The process will not be emotional—it will be arithmetic.